Exhibit 10.1

LICENSE AGREEMENT
[***]: Certain confidential portions of this exhibit were omitted by means of
marking such portions with asterisks because the identified confidential
portions (i) are not material, and (ii) would be competitively harmful if
publicly disclosed.

THIS LICENSE AGREEMENT (this “Agreement”) dated as of July 14, 2016 (the
“Effective Date”), is entered into between TypeZero Technologies LLC, a Delaware
corporation (“TypeZero”), having a place of business at 212 East Main Street,
Suite 202, Charlottesville, VA 22902, and Tandem Diabetes Care, Inc., a Delaware
corporation (“Tandem”), having a place of business at 11045 Roselle Street, San
Diego, CA 92121.
WHEREAS, TypeZero owns or has rights in the Technology (as defined below).
WHEREAS, Tandem desires to obtain a license under TypeZero’s rights in the
Technology on the terms and conditions set forth below.
NOW, THEREFORE, in consideration of the foregoing premises and the mutual
covenants herein contained, the parties hereby agree as follows:
1.DEFINITIONS
For purposes of this Agreement, the terms defined in this Section 1 shall have
the respective meanings set forth below:
1.1“Affiliate” shall mean, with respect to any Person, any other Person that
directly or indirectly controls, is controlled by, or is under common control
with, such Person. A Person shall be regarded as in control of another Person if
it owns, or directly or indirectly controls, at least fifty percent (50%) of the
voting stock or other ownership interest of the other Person, or if it directly
or indirectly possesses the power to direct or cause the direction of the
management and policies of the other Person by any means whatsoever.
1.2“Artificial Pancreas System” means a system that aims to monitor and manage
blood glucose levels via computer algorithms operating on one or more of an
insulin pump or a smartphone or mobile device or other separate remote
controller and to provide insulin and/or other medicaments.
1.3“FDA” shall mean the Food and Drug Administration of the United States, or
the successor thereto.
1.4“Field” shall mean (a) insulin pumps and other medical devices for the
delivery of insulin and/or other medicaments and (b) related software or mobile
applications, in each case in connection with an Artificial Pancreas System.
1.5“First Commercial Sale” shall mean, with respect to any Product, the first
sale of such Product after all applicable marketing and pricing approvals (if
any) have been granted by the applicable governing health authority of such
country.
1.6“Licensed IP Rights” shall mean, collectively, the Licensed Patent Rights and
the Licensed Know-How Rights.
1.7“Licensed Know-How Rights” shall mean all trade secret and other know-how
rights in and to all data, information, compositions and other technology
(including, but not limited to, formulae, procedures, protocols, techniques and
results of experimentation and testing) which are necessary or useful for Tandem
to make, use, develop, sell or seek regulatory approval for a product, or to

1

--------------------------------------------------------------------------------

Exhibit 10.1

practice any method or process, at any time claimed or disclosed in any issued
patent or pending patent application within the Licensed Patent Rights or which
otherwise constitutes or relates to the Technology.
1.8“Licensed Patent Rights” shall mean (a) the patents and patent applications
listed on Exhibit A, (b) all patents and patent applications in any country of
the world that claim or cover the Technology in which TypeZero heretofore or
hereafter has an ownership or (sub)licensable interest, (c) all divisions,
continuations, continuations-in-part, that claim priority to, or common priority
with, the patent applications described in clauses (a) and (b) above or the
patent applications that resulted in the patents described in clauses (a) and
(b) above, and (d) all patents that have issued or in the future issue from any
of the foregoing patent applications, including utility, model and design
patents and certificates of invention, together with any reissues, renewals,
extensions or additions thereto.
1.9“Net Sales” shall mean, with respect to any Product, the gross sales price of
such Product invoiced by Tandem or its Affiliate to customers who are not
Affiliates (or are Affiliates but are the end users of such Product) less, to
the extent actually paid or accrued by Tandem or its Affiliate (as applicable),
(a) credits, allowances, discounts and rebates to, and chargebacks from the
account of, such customers for nonconforming, damaged, outdated and returned
Product; (b) freight and insurance costs incurred by Tandem or its Affiliate (as
applicable) in transporting such Product to such customers; (c) cash, quantity
and trade discounts, rebates and other price reductions for such Product given
to such customers under price reduction programs; (d) sales, use, value-added
and other direct taxes incurred on the sale of such Product to such customers;
(e) customs duties, tariffs, surcharges and other governmental charges incurred
in exporting or importing such Product to such customers; and (f) an allowance
for uncollectible or bad debts determined in accordance with generally accepted
accounting principles. Any deduction referenced in (a) through (f) above that is
not calculated on a per Product basis shall be calculated and reported by Tandem
in good faith and consistent with Tandem’s internal accounting practices and
procedures.
1.10“Person” shall mean an individual, corporation, partnership, limited
liability company, trust, business trust, association, joint stock company,
joint venture, pool, syndicate, sole proprietorship, unincorporated
organization, governmental authority or any other form of entity not
specifically listed herein.
1.11“Pivotal Clinical Trial” shall mean a human clinical trial, the results of
which are sufficient to file a PMA with the FDA.
1.12“Product(s)” shall mean any product in the Field that (a) if made, used,
sold, offered for sale or imported absent the license granted hereunder would
infringe a Valid Claim, or (b) that otherwise uses or incorporates the Licensed
IP Rights.
1.13“Royalty Term” shall mean, commencing on the Effective Date and with respect
to each Product in each country, until [***], unless earlier terminated in
accordance with the provisions of this Agreement.
1.14“Technology” shall mean all software, algorithms, know-how and data
(including clinical data) constituting or related to delivery, management and
monitoring of insulin and/or other medicaments, whether controlled on the device
or by a separate remote controller or mobile device, and related software or
mobile applications, in each case for the management, monitoring or treatment of
diabetes (including both Artificial Pancreas System modules and mobile device
security) and that is first owned or controlled by TypeZero prior to the
Effective Date or within the first five (5) years after the Effective Date,
including without limitation the “UVA Data” and “Related Works” referenced in
the UVA-TypeZero License Agreement (as defined below).
1.15“Territory” shall mean worldwide.
1.16“Third Party” shall mean any Person other than TypeZero, Tandem and their
respective Affiliates.

2

--------------------------------------------------------------------------------

Exhibit 10.1

1.17“Tier 1 License” shall mean a license agreement pursuant to which TypeZero
or its Affiliate grants rights under the Licensed IP Rights for use in the Field
to any of the following entities (or their Affiliates or successors): [***] and
[***] (each a “Tier 1 Licensee”).
1.18“Tier 2 License” shall mean a license agreement pursuant to which TypeZero
or its Affiliate grants rights under the Licensed IP Rights for use in the Field
to any Third Party that is not a Tier 1 Licensee; provided, however, that a
license agreement for [***] shall not constitute a Tier 2 License.
1.19“TypeZero In-Licenses” shall mean all agreements (as modified, amended or
restated as of the Effective Date), pursuant to which TypeZero or its Affiliates
derive any right, title or interest in or to the Licensed IP Rights, including
without limitation the UVA-TypeZero License Agreement (as defined below).
1.20“UC IV Trial” means that certain multi-site International Diabetes
Closed-Loop Trial denominated NIH/NIDDK Grant UC4 DK 108483 sponsored by the
National Institutes of Health and scheduled to run during calendar years 2016
through 2019 (with a project period of 1/1/16 through 12/31/19) and any
extensions thereof, which contemplates a trial of a “control to range” algorithm
application, also known as an artificial pancreas system, that will use
TypeZero’s “inControl AP” running on a smartphone, and which system will be
integrated with an insulin pump and continuous blood glucose monitor from one or
more third-party manufacturers, as well as a cloud-based real-time
monitoring/alerts/database system known as “inControl Cloud.”
1.21“UVA-TypeZero License Agreement” shall mean that certain Amended and
Restated License Agreement by and between the University of Virginia Patent
Foundation d/b/a University of Virginia Licensing and Ventures Group and
TypeZero dated September 4, 2015.
1.22“Valid Claim” shall mean a claim of an issued and unexpired patent included
within the Licensed Patent Rights, which has not been held permanently revoked,
unenforceable or invalid by a decision of a court or other governmental agency
of competent jurisdiction, unappealable or unappealed within the time allowed
for appeal, and which has not been admitted to be invalid or unenforceable
through reissue or disclaimer or otherwise. The invalidity of a particular claim
in one or more countries shall not invalidate such claim in the remaining
countries of the Territory.
2.REPRESENTATIONS AND WARRANTIES
2.1Mutual Representations and Warranties. Each party hereby represents and
warrants to the other party as follows:
2.1.1.Such party is a corporation or limited liability company, as the case may
be, duly organized, validly existing and in good standing under the laws of the
state in which it is incorporated.
2.1.2.Such party (a) has the corporate power and authority and the legal right
to enter into this Agreement and to perform its obligations hereunder, and
(b) has taken all necessary corporate action on its part to authorize the
execution and delivery of this Agreement and the performance of its obligations
hereunder. This Agreement has been duly executed and delivered on behalf of such
party, and constitutes a legal, valid, binding obligation, enforceable against
such party in accordance with its terms.
2.1.3.All necessary consents, approvals and authorizations of all governmental
authorities and other Persons required to be obtained by such party in
connection with this Agreement have been obtained.
2.1.4.The execution and delivery of this Agreement and the performance of such
party’s obligations hereunder (a) do not conflict with or violate any
requirement of applicable laws or regulations, and (b) do not conflict with, or
constitute a default under, any contractual obligation of it.
2.2TypeZero Representations and Warranties. TypeZero hereby represents and
warrants to Tandem that TypeZero has provided Tandem with complete and correct
copies of all TypeZero In-Licenses, and there have been no modifications,
amendments or restatements thereto other than as provided to Tandem prior to the
Effective Date. The TypeZero In-Licenses are in full force and effect in

3

--------------------------------------------------------------------------------

Exhibit 10.1

accordance with their terms. After giving effect to this Agreement, there exist
no breaches, defaults or events that would (with the giving of notice, the
passage of time or both) give rise to a breach, default or other right to
terminate or modify any TypeZero In-License.
3.LICENSE GRANT
3.1.Licensed IP Rights. Effective as of Tandem’s payment of the License Fee set
forth in Section 4.1, TypeZero hereby grants to Tandem a non-exclusive,
non-transferable (subject to Section 10.3 hereof) license (without the right to
grant sublicenses except as set forth below) under the Licensed IP Rights and
solely within the Field to conduct research and to develop, make, have made,
use, offer for sale, sell and import Products in the Territory. The license
grant to use the Licensed IP Rights shall be extended to employees hired by
Tandem or its Affiliates, independent contractors, consultants, and
collaborators solely to the extent that such parties are performing services
for, or working in connection with, Tandem or its Affiliates. Tandem shall also
have the right to grant sublicenses to end users of the Products for the end
users’ use of the Products.
3.2.TypeZero In-Licenses. TypeZero shall timely pay in full all amounts required
to be paid by TypeZero, and timely perform in full all obligations required to
be performed by TypeZero, under all TypeZero In-Licenses. TypeZero promptly
shall provide Tandem with copies of all notices and other deliveries received
under the TypeZero In-Licenses that are material to this Agreement. Without the
prior express written consent of Tandem, TypeZero shall not (and shall take no
action or make no omission to) modify or waive any provision of any TypeZero
In-License that could impair the value of the licenses to Tandem herein, or to
terminate or have terminated any TypeZero In-License. If any TypeZero In-License
is terminated for any reason, TypeZero shall use all commercially reasonable
efforts to cause the licensor thereunder to grant a direct license under the
Licensed IP Rights to Tandem containing terms and conditions no less favorable
to Tandem than the payment terms of such TypeZero In-License.
3.3.Trade Secrets. TypeZero shall maintain in confidence and as a trade secret
the source code of the software and algorithms included within the Technology.
3.4.Availability of the Licensed IP Rights. Promptly following the Effective
Date, TypeZero shall provide Tandem with a copy of all information and
technology available to TypeZero relating to the Licensed IP Rights and
Technology, including without limitation: (a) software and source code,
(b) algorithms, and (c) data (including results of past clinical trials). During
the first five (5) years following the Effective Date, as TypeZero generates or
acquires additional Technology, TypeZero shall promptly provide a copy of such
additional Technology to Tandem.
3.5.Technical Assistance.
3.5.1.During the first [***] following the Effective Date, TypeZero shall
provide to Tandem such technical assistance as is reasonably necessary to enable
Tandem to utilize the Licensed IP Rights and Technology transferred to Tandem
pursuant to Section 3.4, including without limitation providing guidance on the
code and architecture of the applicable software and algorithms. TypeZero shall
provide such initial technical assistance at no additional cost to Tandem,
provided that Tandem shall [***].
3.5.2.During the first five (5) years after the Effective Date, appropriate
representatives of TypeZero and Tandem shall meet in person (at a mutually
agreed upon location) at least [***]. The subject of these meetings will be for
Tandem to report on the status of product development efforts and for TypeZero
to report on the development of additional Technology. Each party will bear its
own costs to prepare and attend such meetings.

4

--------------------------------------------------------------------------------

Exhibit 10.1

3.5.3.If Tandem desires technical assistance or services in addition to that
described in Sections 3.5.1 and 3.5.2 (which may include, without limitation,
product development assistance or clinical trial planning), then TypeZero shall
provide such assistance on a time and materials basis and as mutually agreed
upon by the parties and set forth in a Statement of Work that provides for the
scope of the assistance and services and the applicable budget. Such Statements
of Work shall likewise address ownership of any work product or inventions that
may arise from such assistance and services (including any associated patent and
intellectual property rights), depending upon the nature of the underlying work.
TypeZero shall ensure that any such assistance or services shall be done by
TypeZero personnel that are obligated to assign any inventions to TypeZero, and
TypeZero shall not use any employee of the University of Virginia (or an
employee of any Third Party).
3.5.4.TypeZero shall ensure that at least [***] of the insulin pump products
used in the UC IV Trial are Tandem Products.
3.6.Additional Licenses. TypeZero shall notify Tandem in writing within [***]
following the execution of a Tier 1 License or a Tier 2 License, and shall
specify its identity as one or the other. TypeZero shall not sell its assets or
stock to, and shall not directly or indirectly grant any license or other rights
under the Licensed IP Rights to, [***]. TypeZero shall ensure that with respect
to any agreements that TypeZero enters into with a Third Party to grant a
license to such Third Party under the Licensed IP Rights, if such licensee
acquires, or is acquired by, or otherwise becomes an Affiliate of, [***] then
such agreement shall terminate.
3.7.New IP. If, after five (5) years following the Effective Date, [***] (“New
IP”), then TypeZero shall notify Tandem in writing of such New IP within [***]
following the date of development or acquisition thereof. TypeZero hereby grants
to Tandem for a period of [***] following the date TypeZero provides such notice
with respect to any New IP (the “Negotiation Period”), a right to [***]. During
the applicable Negotiation Period, the parties shall negotiate in good faith and
attempt to reach mutual agreement on commercially reasonable terms and
conditions for [***]. If the parties are unable to agree upon such terms and
conditions during the applicable Negotiation Period, then TypeZero may [***];
provided, however, that if [***].
3.8.Enforcement and Licensing of Patent Rights. Subject in all events to the
attorney-client privilege (which TypeZero expressly reserves), TypeZero shall
provide notice to Tandem within [***]. In such case, TypeZero shall [***]
including, without limitation, to (a) [***], or (b) [***] to the extent
permissible under this Agreement. TypeZero shall, however, [***], and shall
notify Tandem promptly in the event of any such action. If TypeZero does not do
either (a) or (b) by the end of [***], then for purposes of [***] TypeZero shall
be deemed to have [***].
4.FINANCIAL CONSIDERATIONS
4.1.License Fee. Within [***] following the Effective Date, Tandem shall pay to
TypeZero an upfront license fee of [***].

5

--------------------------------------------------------------------------------

Exhibit 10.1

4.2.Royalties.
4.2.1.Royalty Rate.
a.With respect to Products and during the applicable Royalty Term for such
Products, Tandem shall pay to TypeZero royalties, with respect to such Products,
equal to (i) [***] of aggregate Net Sales of such Products by Tandem and its
Affiliates up to [***] of aggregate Net Sales, and (ii) [***] of aggregate Net
Sales of such Products by Tandem and its Affiliates above [***]. Only one
royalty shall be owing for a Product regardless of how many Valid Claims cover
such Product, and regardless of whether Tandem provides an update or upgrade to
such Product with updated Technology. For the avoidance of doubt, and
notwithstanding anything in this Agreement to the contrary, the parties mutually
acknowledge and agree that Tandem shall have no obligation to pay royalties
under this Agreement for any Tandem products that (i) are [***], recognizing
that such product is likely to undergo revisions or modifications to hardware or
software from time to time, including changes needed for interoperability with
alternative continuous glucose sensors and/or other blood glucose monitoring
devices (a “Tandem PLGS System”), and (ii) are not intended for use with, or
otherwise marketed by Tandem to be used as part of, a [***].
b.Commencing with aggregate Net Sales above [***], the applicable royalty rate
set forth in Section 4.2.1(a) shall be reduced by [***] in each instance that
(i) TypeZero grants a Tier 1 License after the first (1st) Tier 1 License is
granted, and/or (ii) TypeZero grants a Tier 2 License after the second (2nd)
Tier 2 License is granted, for so long as each such Tier 1 License or Tier 2
License continues in effect (provided that (i) if any such Tier 1 License or
Tier 2 License is terminated, then the applicable reduction will no longer apply
starting with the next calendar quarter after the date of termination, and (ii)
if a Tier 1 License or Tier 2 License is terminated as a result of a change of
control or merger of TypeZero with another licensee under a Tier 1 License or
Tier 2 License, or as a result of a change of control or merger of a licensee
under a Tier 1 License or Tier 2 License with another licensee under a Tier 1
License or Tier 2 License, then the reduction shall continue); provided,
however, that Tandem shall [***]. By way of example, if TypeZero grants [***],
then the applicable royalty rate set forth in Section 4.2.1(a) shall be reduced
by [***].
c.The royalty owing Section 4.2.1(a) is due on Products that at the time of sale
are covered by a Valid Claim in the country of manufacture or sale during the
applicable Royalty Term. If Tandem provides and update or upgrade to a product
that was not previously subject to a royalty under Section 4.2.1(a), but after
receiving the update or upgrade such product would constitute a Product that at
the time of upgrade or update, as the case may be, is covered by a Valid Claim
in the country of manufacture or sale, then Tandem shall pay to TypeZero a
royalty equal to: (i) if Tandem [***] (subject to standard deductions as set
forth in the Net Sales definition), or (ii) if Tandem [***] (subject to standard
deductions as set forth in the Net Sales definition).
d.If at any time TypeZero has granted more than [***] Tier 1 Licenses and Tier 2
Licenses in any combination, then-upon the date that TypeZero notifies Tandem of
the [***] such license pursuant to Section 3.6 hereof-Tandem shall receive a
credit against future royalties equal to [***]. Tandem shall not have the right
to take the foregoing credit until Tandem shall have achieved [***] in aggregate
Net Sales of Product and, thereafter, Tandem shall have the right to take such
credit against any subsequent royalty payments until fully credited.
4.2.2.Third Party Royalties. If Tandem or its Affiliates are required to pay
royalties to any Third Party in order to exercise its rights hereunder to make,
have made, use, sell, offer to sale or import any Product, then Tandem shall
have the right to credit [***] of such Third Party royalty payments against the
royalties owing to TypeZero under Section 4.2.1 with respect to sales of such
Product in such country; provided, however, that Tandem shall not reduce the
amount of the royalties paid to TypeZero under Section 4.2.1 by reason of this
Section 4.2.2, with respect to sales of such Product in such country, to less
than [***] of the royalties that would otherwise be due under Section 4.2.1.

6

--------------------------------------------------------------------------------

Exhibit 10.1

4.3.Combination Products. If a Product consists of components that are covered
by a Valid Claim and components that are not covered by a Valid Claim, then for
purposes of the royalty payments under Section 4.2 for Net Sales of such
Products, such Net Sales, prior to the royalty calculation set forth in
Section 4.2, first shall be [***] as reasonably determined by Tandem, and such
resulting amount shall be the “Net Sales” for purposes of the royalty
calculation in Section 4.2 for such Product. For clarity, no royalty is due on
sales of accessories such as infusion sets, cartridges, CGM sensors, CGM
transmitters or CGM receivers not integrated into a pump.
4.4.Milestones. Tandem shall pay to TypeZero the following [***] milestone
payments within [***] days following the first achievement of the applicable
milestone by Tandem:
Milestone #
Milestone Event
Milestone Payment
1
Generation of data under the UC IV Trial sufficient for Tandem to initiate a
Pivotal Clinical Trial for a Product, which shall be deemed to be data from
[***]or approximately [***].
USD $[***]*
2
Enrollment of first patient in a Pivotal Clinical Trial for the first Product
(excluding consumables such as cartridges, infusion sets and other accessories)
that utilizes the Technology and is covered by a Valid Claim
USD $[***]
3
Receipt of approval from the FDA for a PMA for the first Product (excluding
consumables such as cartridges, infusion sets and other accessories) that
utilizes the Technology and is covered by a Valid Claim
USD $[***]

* In the event that TypeZero does not achieve Milestone #1 on or before [***]
(the “Milestone 1 Date”), the Milestone Payment for Milestone #1 shall be
reduced by [***]; provided, however, that if [***].
4.5.Supply of Materials. Upon request, Tandem agrees to supply to TypeZero, or
its designee, with up to [***] and up to [***] for use in the performance of the
UC IV Trial, subject to the terms of a material transfer agreement in a form
reasonably acceptable to both parties with terms that are customary for the
performance of a human clinical study of an unapproved product. Any such
materials may not be used for any purpose other than the performance of the UC
IV Trial. The materials supplied hereunder shall be deemed to have a fair market
value of [***]. Any additional [***] shall be purchased from Tandem at a price
of [***] and [***] and on such other terms that are consistent with the above
referenced material transfer agreement.
4.6.[***]. If at any time during the term of this Agreement TypeZero [***], or
any combination thereof when viewed as whole-and in light of potential market
opportunity) for a grant of a license under the Licensed IP Rights to any Third
Party that are [***], TypeZero shall also [***] to Tandem, and if Tandem [***],
the parties shall amend this Section 4 to reflect such terms, such amendment to
be effective as of the date TypeZero and Tandem both sign the same.
4.7.Sale of Company. During the term of this Agreement, and subject in all
events to confidentiality obligations and the attorney-client privilege (which
TypeZero expressly reserves) and contractual obligations to the contrary (such
as “no shop” provisions and the like), should TypeZero intend to accept an offer
from any potential buyer for the sale of all or part of TypeZero’s business
(whether by asset sale, merger, reorganization, change of control, operation of
law or otherwise) (a “Third Party Offer”), TypeZero shall notify Tandem of such
state of affairs; provided, however, that TypeZero need not identify the
potential buyer or otherwise provide to Tandem the terms and conditions of such
Third Party Offer. TypeZero will consider in good faith any proposed
counter-offer from Tandem to the Third Party Offer and any modifications
thereof; provided, however, that Tandem shall have no obligation to make any
offer to acquire all or any part of TypeZero’s business.

7

--------------------------------------------------------------------------------

Exhibit 10.1

5.ROYALTY REPORTS AND ACCOUNTING
5.1.Royalty Reports. Within [***] after the end of each calendar [***] during
the term of this Agreement following first to occur of the First Commercial Sale
of a Product, Tandem shall furnish to TypeZero a [***] written report showing in
reasonably specific detail (a) the calculation of Net Sales during such calendar
quarter; (b) the calculation of the royalties, if any, that shall have accrued
based upon such Net Sales; (c) the withholding taxes, if any, required by law to
be deducted with respect to such sales; and (d) the exchange rates, if any, used
in determining the amount of United States dollars. With respect to sales of
Products invoiced in United States dollars, the gross sales, Net Sales and
royalties payable shall be expressed in United States dollars. With respect to
Net Sales invoiced in a currency other than United States dollars, all such
amounts shall be expressed both in the currency in which the distribution is
invoiced and in the United States dollar equivalent. The United States dollar
equivalent shall be calculated using the average of the exchange rate (local
currency per US$1) published in The Wall Street Journal, Western Edition, under
the heading “Currency Trading” on the last business day of each month during the
applicable calendar quarter.
5.2.Audits.
5.2.1.Upon the written request of TypeZero and not more than [***], Tandem shall
permit an independent certified public accounting firm of nationally recognized
standing selected by TypeZero and reasonably acceptable to Tandem, [***], to
have access during normal business hours to such of the financial records of
Tandem as may be reasonably necessary to verify the accuracy of the payment
reports hereunder for the [***] immediately prior to the date of such request
(other than records for which TypeZero has already conducted an audit under this
Section.
5.2.2.If such accounting firm concludes that additional amounts were owed during
the audited period, Tandem shall pay such additional amounts within [***] after
the date TypeZero delivers to Tandem such accounting firm’s written report so
concluding. The fees charged by such accounting firm shall be paid by TypeZero;
provided, however, if the audit discloses that the royalties payable by Tandem
for such period are more than [***] of the royalties actually paid for such
period, then Tandem shall pay the reasonable fees and expenses charged by such
accounting firm.
5.2.3.TypeZero shall cause its accounting firm to retain all financial
information subject to review under this Section 5.2 in strict confidence;
provided, however, that Tandem shall have the right to require that such
accounting firm, prior to conducting such audit, enter into an appropriate
non-disclosure agreement with Tandem regarding such financial information. The
accounting firm shall disclose to TypeZero only whether the reports are correct
or not and the amount of any discrepancy. No other information shall be shared.
TypeZero shall treat all such financial information as Tandem’s Confidential
Information.
6.PAYMENTS
6.1.Payment Terms. Royalties shown to have accrued by each royalty report
provided for under Section 5 shall be due on the date such royalty report is
due. Payment of royalties in whole or in part may be made in advance of such due
date.
6.2.Exchange Control. If at any time legal restrictions prevent the prompt
remittance of part or all royalties with respect to any country in the Territory
where the Product is sold, Tandem shall have the right, in its sole discretion,
to make such payments by depositing the amount thereof in local currency to
TypeZero’s account in a bank or other depository institution in such country. If
the royalty rate specified in this Agreement should exceed the permissible rate
established in any country, the royalty rate for sales in such country shall be
adjusted to the highest legally permissible or government-approved rate.

8

--------------------------------------------------------------------------------

Exhibit 10.1

6.3.Withholding Taxes. Tandem shall be entitled to deduct the amount of any
withholding taxes, value-added taxes or other taxes, levies or charges with
respect to such amounts, other than United States taxes, payable by Tandem, its
Affiliates or sublicensees, or any taxes required to be withheld by Tandem, its
Affiliates or sublicensees, to the extent Tandem, its Affiliates or sublicensees
pay to the appropriate governmental authority on behalf of TypeZero such taxes,
levies or charges. Tandem shall use reasonable efforts to minimize any such
taxes, levies or charges required to be withheld on behalf of TypeZero by
Tandem, its Affiliates or sublicensees. Tandem promptly shall deliver to
TypeZero proof of payment of all such taxes, levies and other charges, together
with copies of all communications from or with such governmental authority with
respect thereto.
7.CONFIDENTIALITY
7.1.Confidential Information. During the term of this Agreement, and for a
period of [***] following the expiration or earlier termination hereof, each
party shall maintain in confidence all information of the other party that is
disclosed by the other party and identified as, acknowledged to be, or
reasonably should be considered confidential at the time of disclosure (the
“Confidential Information”), and shall not use, disclose or grant the use of the
Confidential Information except on a need-to-know basis to those directors,
officers, affiliates, employees, permitted licensees, permitted assignees and
agents, consultants, clinical investigators or contractors, to the extent such
disclosure is reasonably necessary in connection with performing its obligations
or exercising its rights under this Agreement. To the extent that disclosure is
authorized by this Agreement, prior to disclosure, each party hereto shall
obtain agreement of any such Person to hold in confidence and not make use of
the Confidential Information for any purpose other than those permitted by this
Agreement. Each party shall notify the other promptly upon discovery of any
unauthorized use or disclosure of the other party’s Confidential Information.
7.2.Permitted Disclosures. The confidentiality obligations contained in
Section 7.1 shall not apply to the extent that (a) any receiving party (the
“Recipient”) is required (i) to disclose information by law, regulation or order
of a governmental agency or a court of competent jurisdiction, or (ii) to
disclose information to any governmental agency for purposes of obtaining
approval to test or market a product, provided in either case that the Recipient
shall provide written notice thereof to the other party and sufficient
opportunity to object to any such disclosure or to request confidential
treatment thereof; or (b) the Recipient can demonstrate that (i) the disclosed
information was public knowledge at the time of such disclosure to the
Recipient, or thereafter became public knowledge, other than as a result of
actions of the Recipient in violation hereof; (ii) the disclosed information was
rightfully known by the Recipient (as shown by its written records) prior to the
date of disclosure to the Recipient by the other party hereunder; (iii) the
disclosed information was disclosed to the Recipient on an unrestricted basis
from a source unrelated to any party to this Agreement and not under a duty of
confidentiality to the other party; or (iv) the disclosed information was
independently developed by the Recipient without use of the Confidential
Information disclosed by the other party. Notwithstanding any other provision of
this Agreement, Tandem may disclose Confidential Information of the TypeZero
relating to information developed pursuant to this Agreement to any Person with
whom Tandem has, or is proposing to enter into, a business relationship, as long
as such Person has entered into a confidentiality agreement with Tandem. All
Confidential Information of both parties shall be returned or, at the disclosing
party’s option destroyed, by within a prompt and commercially reasonable time
after this Agreement terminates for any reason; provided, however, that a
Recipient (A) may retain one (1) copy for its legal archival purposes, (B) will
not be required to remove electronic files, and (C) will not be required to
return or destroy records that it is required to maintain under applicable laws,
rules, or regulations, including, without limitation, records in a Party’s
quality systems relating to Products.

9

--------------------------------------------------------------------------------

Exhibit 10.1

7.3.Terms of this Agreement. Except as otherwise provided in Section 7.2,
TypeZero and Tandem shall not disclose any terms or conditions of this Agreement
to any Third Party without the prior consent of the other party. Notwithstanding
the foregoing, prior to execution of this Agreement, Tandem and TypeZero have
agreed upon the substance of information that can be used to describe the terms
of this transaction, and Tandem and TypeZero may disclose such information, as
modified by mutual agreement from time to time, without the other party’s
consent.
8.TERMINATION
8.1.Expiration. Subject to Sections 8.2 and 8.3 below, this Agreement shall
expire on [***]. Upon such expiration of this Agreement, Tandem shall have a
fully paid-up, non-exclusive license under the Licensed Know-How Rights to
conduct research and to develop, make, have made, use, sell, offer for sale and
import Products in the Territory for use in the Field.
8.2.Termination by Tandem. Tandem may terminate this Agreement, in its sole
discretion, upon [***] prior written notice to TypeZero; provided, however, that
any amounts paid by Tandem to TypeZero pursuant to Section 4 of this Agreement
or otherwise shall be nonrefundable.
8.3.Termination for Cause. Except as otherwise provided in Section 9, TypeZero
may terminate this Agreement upon or after the breach of any material provision
of this Agreement by Tandem if Tandem has not cured such breach within [***]
after receipt of express written notice thereof by TypeZero; provided, however,
if any default is not capable of being cured within such [***] period and Tandem
is diligently undertaking to cure such default as soon as commercially feasible
(but not more than [***] thereafter under the circumstances, TypeZero shall have
no right to terminate this Agreement. If TypeZero terminates this Agreement, any
amounts paid by Tandem to TypeZero pursuant to Section 4 of this Agreement or
otherwise shall be nonrefundable.
8.4.Effect of Expiration or Termination. Expiration or termination of this
Agreement shall not relieve the parties of any obligation accruing prior to such
expiration or termination, and the provisions of Sections [***] and [***] shall
survive the expiration or termination of this Agreement.
9.FORCE MAJEURE
Neither party shall be held liable or responsible to the other party nor be
deemed to have defaulted under or breached this Agreement for failure or delay
in fulfilling or performing any term of this Agreement to the extent, and for so
long as, such failure or delay is caused by or results from causes beyond the
reasonable control of the affected party including but not limited to fire,
floods, embargoes, war, acts of war (whether war be declared or not), acts of
terrorism, insurrections, riots, civil commotions, strikes, lockouts or other
labor disturbances, acts of God or acts, omissions or delays in acting by any
governmental authority or the other party.
10.MISCELLANEOUS
10.1.Notices. Any consent, notice or report required or permitted to be given or
made under this Agreement by one of the parties hereto to the other party shall
be in writing, delivered by any lawful means to such other party at its address
indicated below, or to such other address as the addressee shall have last
furnished in writing to the addressor and (except as otherwise provided in this
Agreement) shall be effective upon receipt by the addressee.

If to TypeZero:    TypeZero Technologies LLC
212 East Main Street, Suite 202
Charlottesville, VA 22902
Attention: Chad Rogers, President and CEO

10

--------------------------------------------------------------------------------

Exhibit 10.1

With a copy to:    Kevin L. Passarello
Buchanan Ingersoll & Rooney, PC
1700 K Street, NW, Suite 300
Washington, DC 20006

If to Tandem:        Tandem Diabetes Care, Inc.
11045 Roselle Street
San Diego, California 92121
Attention: Chief Executive Officer
With a copy to:    Tandem Diabetes Care, Inc.
11045 Roselle Street
San Diego, California 92121
Attention: General Counsel
10.2.Governing Law. This Agreement shall be governed by and construed in
accordance with the laws of the State of [***], without regard to the conflicts
of law principles thereof.
10.3.Assignment. Neither party shall assign its rights or obligations under this
Agreement without the prior written consent of the other party; provided,
however, that a party may, without such consent, assign this Agreement and its
rights and obligations hereunder (a) to any Affiliate, or (b) in connection with
the transfer or sale of all or substantially all of its business to which this
Agreement relates, or in the event of its merger, consolidation, change in
control or similar transaction. Any permitted assignee shall assume all
obligations of its assignor under this Agreement.
10.4.Waivers and Amendments. No change, modification, extension, termination or
waiver of this Agreement, or any of the provisions herein contained, shall be
valid unless made in writing and signed by duly authorized representatives of
the parties hereto.
10.5.Entire Agreement. This Agreement embodies the entire agreement between the
parties and supersedes any prior representations, understandings and agreements
between the parties regarding the subject matter hereof. There are no
representations, understandings or agreements, oral or written, between the
parties regarding the subject matter hereof that are not fully expressed herein.
10.6.Bankruptcy. The foregoing license is and shall be deemed to be, for
purposes of 11 U.S.C. Section 365(n), a license of “Intellectual Property
Rights” as defined thereunder, and if TypeZero is under any proceeding under the
United States Bankruptcy Code and the trustee in bankruptcy of TypeZero, or
TypeZero as a debtor in possession, elects to reject the foregoing license,
Tandem may, pursuant to 11 U.S.C. Section 365(n)(1) and (2), retain any and all
of Tandem’s rights under such license to the maximum extent permitted by law.
10.7.Severability. Any of the provisions of this Agreement that are determined
to be invalid or unenforceable in any jurisdiction shall be ineffective to the
extent of such invalidity or unenforceability in such jurisdiction, without
rendering invalid or unenforceable the remaining provisions hereof and without
affecting the validity or enforceability of any of the terms of this Agreement
in any other jurisdiction.
10.8.Waiver. The waiver by either party hereto of any right hereunder or the
failure to perform or of a breach by the other party shall not be deemed a
waiver of any other right hereunder or of any other breach or failure by said
other party whether of a similar nature or otherwise.
10.9.Counterparts. This Agreement may be executed in two or more counterparts,
each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument.

11

--------------------------------------------------------------------------------

Exhibit 10.1

IN WITNESS WHEREOF, the parties have executed this Agreement effective as of the
Effective Date.
TYPEZERO TECHNOLOGIES, LLC
By: /s/ Chad Rogers
Name: Chad Rogers
Title: CEO
Date: 7/14/2016

TANDEM DIABETES CARE, INC.
By: /s/ Kim D. Blickenstaff
Name: Kim D. Blickenstaff
Title CEO
Date: 7/14/2016

12

--------------------------------------------------------------------------------

Exhibit 10.1

EXHIBIT A
[***]

13